Ann Katherine M. Foreman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ann Katherine M. Foreman has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Christine Rini
Northwestern University Feinberg School of Medicine
3 shared publications - Jonathan S. Berg
University of North Carolina at Chapel Hill
3 shared publications - Kristy Lee
University of North Carolina at Chapel Hill
3 shared publications - Margaret Waltz
University of North Carolina at Chapel Hill
3 shared publications - Myra I. Roche
Center for Genomics and Society, University of North Carolina, Chapel Hill, NC, USA
3 shared publications - Amanda S. Freed
Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, CA 91101 , USA
2 shared publications
Latest Publications
- 4 March 2025
- Published by Taylor & Francis in Personalized Medicine
- Vol. 22 (2) , 93-101
How people undergoing genomic sequencing interpret and react to varied secondary findings with limited actionability
To investigate patient reactions to and understanding of secondary genomic findings with limited to no medical actionability (LMA-SFs) from diagnostic genome sequencing. We analyzed LMA-SFs returned to 47 adults who elected to receive a broad set of these results from 6 categories. Findings indicated elevated risk (reportable/positive) or not (negative/normal). Most participants (N = 43) also completed surveys to report their distress, decision regret, expected health anxiety, and whether and how they perceived results as reassuring or troubling. Most participants received some reportable LMA-SFs for common risk, pharmacogenetic, and carrier status variants. Fewer received reportable APOE haplotype or monogenetic condition variants. None received results indicating high risk for severe neurological disease. Overall, participants (76.7% female, 97.7% White) had low distress, decision regret, and expected health anxiety. None described negative/normal findings as troubling. However, their interpretations of reportable/positive results varied. Even within the same result type, some participants found them troubling, while others found them reassuring based on their perception of the results' utility. Participants' short-term well-being was not reduced by receiving LMA-SFs. Their interpretations suggested varied personal utilities and the need for post-test resources to aid understanding of these types of results and their health significance.
- 4 March 2025
- Published by Taylor & Francis in Personalized Medicine
- Vol. 22 (2) , 93-101
How people undergoing genomic sequencing interpret and react to varied secondary findings with limited actionability
To investigate patient reactions to and understanding of secondary genomic findings with limited to no medical actionability (LMA-SFs) from diagnostic genome sequencing. We analyzed LMA-SFs returned to 47 adults who elected to receive a broad set of these results from 6 categories. Findings indicated elevated risk (reportable/positive) or not (negative/normal). Most participants (N = 43) also completed surveys to report their distress, decision regret, expected health anxiety, and whether and how they perceived results as reassuring or troubling. Most participants received some reportable LMA-SFs for common risk, pharmacogenetic, and carrier status variants. Fewer received reportable APOE haplotype or monogenetic condition variants. None received results indicating high risk for severe neurological disease. Overall, participants (76.7% female, 97.7% White) had low distress, decision regret, and expected health anxiety. None described negative/normal findings as troubling. However, their interpretations of reportable/positive results varied. Even within the same result type, some participants found them troubling, while others found them reassuring based on their perception of the results' utility. Participants' short-term well-being was not reduced by receiving LMA-SFs. Their interpretations suggested varied personal utilities and the need for post-test resources to aid understanding of these types of results and their health significance.
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S125-S126
ClinGen’s actionability working groups: development and early implementation of an assertion rubric for clinical actionability
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S125-S126
ClinGen’s actionability working groups: development and early implementation of an assertion rubric for clinical actionability
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S67-S68
Clinical actionability of secondary findings in the pediatric context
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S67-S68
Clinical actionability of secondary findings in the pediatric context
- 1 January 2020
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 60-68
Genomic knowledge in the context of diagnostic exome sequencing: changes over time, persistent subgroup differences, and associations with psychological sequencing outcomes
- 1 January 2020
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 60-68
Genomic knowledge in the context of diagnostic exome sequencing: changes over time, persistent subgroup differences, and associations with psychological sequencing outcomes